Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
GSS Stock Chart & Stats
AU$0.24
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.24
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.69
Previous CloseN/A
Volume34.30K
Average Volume (3M)149.45K
Market Cap
AU$18.17M
Enterprise ValueAU$1.63M
Total Cash (Recent Filing)AU$29.87M
Total Debt (Recent Filing)AU$653.00K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$17.10M
Bulls Say, Bears Say
Bulls Say
Proprietary 3base Technology & Recurring ConsumablesGSS's 3base™ platform and multiplex PCR panels create a recurring consumables business model: labs repurchase kits as they test patients. Combined with software and lab integration, this raises switching costs and supports durable per-test revenue as adoption expands across clinical labs and public health networks.
Positive Revenue Growth TrendConsistent revenue growth (latest-year +8.45%) indicates increasing assay adoption and deeper penetration of target markets. Sustained top-line growth provides a foundation for scaling operating leverage if GSS can convert adoption into higher volumes and amortize fixed R&D and commercial costs over larger sales.
Low Leverage / Solid Equity PositionVery low debt affords financial flexibility and lowers bankruptcy risk, giving management runway to invest in commercialization, regulatory filings, and partnerships without immediate refinancing pressure. A strong equity base supports strategic initiatives and withstands cyclical testing demand.
Bears Say
Persistent Negative ProfitabilityDespite revenue growth, the company consistently posts negative net, EBIT and EBITDA margins, showing it cannot yet convert sales into sustainable operating profits. Long-term viability depends on reversing this trend through scale, pricing or cost control to fund R&D and commercial expansion internally.
Negative Operating And Free Cash FlowsOngoing negative operating and free cash flows signal cash burn; even with low debt, sustained negative cash generation necessitates external funding or equity raises. This constrains strategic choices, may dilute shareholders, and limits the company's ability to self-fund regulatory and commercial investments.
Revenue Seasonality And Distribution RelianceSales depend on testing volumes that are seasonal and outbreak-driven and on third-party distributors for geographic reach. This creates demand volatility and execution risk: uneven consumption cycles hurt predictability, and distributor dependence can limit margin capture and slow market development.
Genetic Signatures Ltd. News
GSS FAQ
What was Genetic Signatures Ltd.’s price range in the past 12 months?
Genetic Signatures Ltd. lowest share price was AU$0.07 and its highest was AU$0.69 in the past 12 months.
What is Genetic Signatures Ltd.’s market cap?
Genetic Signatures Ltd.’s market cap is AU$18.17M.
When is Genetic Signatures Ltd.’s upcoming earnings report date?
Genetic Signatures Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 146 days.
How were Genetic Signatures Ltd.’s earnings last quarter?
Genetic Signatures Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.028.
Is Genetic Signatures Ltd. overvalued?
According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued.
Does Genetic Signatures Ltd. pay dividends?
Genetic Signatures Ltd. does not currently pay dividends.
What is Genetic Signatures Ltd.’s EPS estimate?
Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Signatures Ltd. have?
Genetic Signatures Ltd. has 227,138,820 shares outstanding.
What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?
Genetic Signatures Ltd. reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of Genetic Signatures Ltd.?
Currently, no hedge funds are holding shares in AU:GSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genetic Signatures Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:GSS Sentiment 66%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.35%
12-Months-Change
Fundamentals
Return on Equity
-23.93%
Trailing 12-Months
Asset Growth
-16.90%
Trailing 12-Months
Company Description
Genetic Signatures Ltd.
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Inoviq Ltd
―